Business
Mesoblast scores US regulatory breakthrough – The Australian Financial Review
Mesoblast has scored a win in marketing its stem cell therapy drug in the US after a verdict was delivered about 7am AEST.
A US healthcare Oncologic Drugs Advisory Committee (ODAC) meeting has voted eight to two in favour of a Mesoblast drug to treat transplant rejections in children.
The verdict was delivered about 7am AEST after the US Food and Drug Administration’s (FDA) Advisory Committee majority voted the available clinical data supplied by Mesoblast support the efficacy of its Ryoncil drug in pediatric patients with acute-Graft Versus Host Disease (aGVHD).
The final decision on whether to approve Mesoblast’…
-
Noosa News13 hours agoTwo in five Brisbane streets have no footpaths, with council building about 4km of new paths last year
-
Business22 hours agoWhere to invest $20,000 in ASX ETFs for 2026 and beyond
-
Noosa News23 hours agoQueensland Police Commissioner Steve Gollschewski to return to work after ‘second chance at life’
-
General21 hours agoReece Walsh grabs the Sun to lead Brisbane to an all-time victory over Canberra